LDS/Medical Tests/TGFBR1 Gene Mutation Analysis

TGFBR1 Gene Mutation Analysis

The TGFBR1 gene is located on the long (q) arm of chromosome 9 at position 22.33 and encodes transforming growth factor (TGF), beta-receptor 1. This protein belongs to the Ser/Thr protein kinase family and has a protein kinase domain, forms a heterodimeric complex with type II TGF-β receptor protein, and binds TGF-beta. This TGF-β receptor complex phosphorylates proteins and transmits a signal which triggers various responses by the cell, including the growth and division (proliferation) of cells, the maturation of cells to carry out specific functions (differentiation), cell movement (motility), and controlled cell death (apoptosis). It can suppress the formation of tumors by preventing uncontrolled growth of cells. Mutations in this gene are associated with Loeys-Deitz Syndrome (LDS), Multiple self-healing squamous epithelioma (MSSE or Familial keratoacanthoma), familial thoracic aortic aneurysms and dissections (TAAD) and prostate cancer.

Loeys-Dietz syndrome is an autosomal dominant disorder that affects connective tissue and blood vessel of the body. Approximately 25% of LDS patients have an affected parent while 75% are due to de-novo mutations. TGFBR1 gene mutations that cause Loeys-Dietz type 1 syndrome change a single amino acid in the TGF-β1 protein, resulting in a receptor that can bind its ligand but fails to transmit the intracellular signal. Surprisingly, and perhaps due to dysregulated compensatory mechanisms, there is an apparent increase in TGFβ signaling intracellularly that results in the clinical manifestations of the disorder.

LDS is characterized by vascular findings (cerebral, thoracic, and abdominal arterial aneurysms and/or dissections), skeletal manifestations (pectus excavatum or pectus carinatum, scoliosis, joint laxity, arachnodactyly, talipes equinovarus, cervical spine malformation and/or instability), craniofacial features (widely spaced eyes, strabismus, bifid uvula / cleft palate, and craniosynostosis that can involve any cranial suture), and cutaneous findings (velvety and translucent skin, easy bruising, and dystrophic scars). Individuals with LDS are predisposed to widespread and aggressive arterial aneurysms and pregnancy-related complications including uterine rupture and death. Individuals with LDS can show a strong predisposition for allergic/inflammatory disease including asthma, eczema, and reactions to food or environmental allergens. There is also an increased incidence of gastrointestinal inflammation including eosinophilic esophagitis and gastritis or inflammatory bowel disease. Multiple self-healing squamous epithelioma (MSSE), also known as Ferguson-Smith disease or Familial keratoacanthoma, is characterized by the formation of multiple invasive squamous tumors that grow uncontrollably for a few weeks and suddenly shrink and die off, leaving a scar. Mutations associated with this disorder cause a complete lack of functional receptor, a total loss of TGF-β pathway signaling and severely reduced tumor suppression.

Familial thoracic aortic aneurysm and dissection (familial TAAD) involves a permanent, localized dilatation of the thoracic aorta and stretching of the aorta that may lead to a sudden tearing of the layers in the aorta wall (aortic dissection). Aortic aneurysm and dissection can cause life-threatening internal bleeding. The TGFBR1 gene mutations that cause familial TAAD disrupt signal transduction, which can impair cell growth and development. Up to 20% of individuals with TAAD who do not have a known syndrome (e.g., Marfan syndrome, vascular Ehlers-Danlos syndrome, or Loeys-Dietz syndrome) have a family history of TAAD.

  • Diagnosis of TGFBR1-associated Loeys-Dietz syndrome
  • As an aid in diagnosis of Marfan or Marfan-like syndrome and familial thoracic aortic aneurysm and dissection syndrome
  • To diagnose Ferguson-Smith disease and prostate cancers with TGFBR1 gene mutation
  • To identify carrier of the familial TGFBR1 mutation by predictive testing in family members
  • For the prenatal genetic test in an individual at risk of familial TAAD
  • To assist with prognosis, clinical management and surveillance for disease features based on the genetic variant involved
Mutation or pathogenic variant in TGFBR1 gene. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.

Negative for mutations or pathogenic variants

Sequence analysis by next generation sequencing or bi-directional sequencing. TGFBR1 gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.

Whole blood, amniotic fluid (prenatal test). 

Stability

  • Ambient: 72 hours
  • Refrigerated: 1 week
  • Frozen: Unacceptable
Echocardiography, computed tomography (CT), MRI, Angiography, Cardiac panel, TGFBR1, TGFBR2, FBN1, ACTA2 and MYH11 mutation analysis for aortic aneurysms and aortic dissections, Comprehensive Skeletal Dysplasias and Disorders Panel, Ehlers-Danlos Syndrome Panel, Marfan Syndrome Panel, Comprehensive Growth Disorders / Skeletal Dysplasias and Disorders Panel, Craniosynostosis Panel, Aorta Panel.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login